Skip to main content
. 2015 Aug 26;10(5):3137–3144. doi: 10.3892/ol.2015.3644

Figure 2.

Figure 2.

(A) The expression of HO-1 mRNA in normal, favorable, intermediate and adverse risk patient groups. (B) The expression of RET mRNA in normal, favorable, intermediate and adverse risk patient groups. (C) The expression of PML mRNA in normal, favorable, intermediate and adverse risk patient groups. Statistical significance was determined by the one-way ANOVA analysis and q-text. The data is represented as the mean ± standard deviation from 3 independent experiments. HO-1, Heme oxygenase-1. RET, a tyrosine kinase receptor. PML, Promyelocytic leukemia gene. *P<0.05; **P<0.01.